Drugs / ZED1227
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05818956 | May → Jun 2023 | — | Takeda | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07298343 | Jun 2024 → Aug 2027 expected | celiac disease | Dr. Falk Pharma GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT05305599 | Apr 2022 → Jun 2023 | fatty liver disease, fibrotic liver disease | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-20 | Takeda | Regulatory Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy takeda.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-10-20 | Takeda | Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy takeda.com ↗ |
| 2022-07-01 | Dr. Falk Pharma GmbH | NAFLD: Phase 2a proof of concept study of ZED1227 drfalkpharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZED1227 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05305599 ↗ |
| Known as | TAK-227 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05818956 ↗ |
| Action | Inhibit | “designed to inhibit the activity of human tissue transglutaminase 2 (TG2)” NCT05305599 ↗ |
| Modality | Small molecule | — CHEMBL4081588 ↗ |
| Route | Oral | “oral treatment” NCT05305599 ↗ |